Straits Times Index
3,327.70 +9.25 (+0.28%) S&P 500
5,304.72 +36.88 (+0.70%) Dow
39,069.59 +4.29 (+0.01%) Nasdaq
16,920.79 +184.79 (+1.10%) Bitcoin USD
68,032.68 -557.04 (-0.81%) CMC Crypto 200
1,481.70 -14.76 (-0.99%)
LLY Jan 2026 270.000 put
| Previous close | 1.9000 |
| Open | 2.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 270.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.5400 - 2.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksEli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
Insider MonkeyThe Biggest Publicly Traded Biotech Company
In this article, we will be discussing the biggest publicly traded biotech company that ranks at the top of our free list of the 20 Biggest Publicly Traded Biotech Companies. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate […]
BenzingaEli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds
Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion. This expansion will enhance Lilly’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Related: Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires M
